Aldosterone synthase inhibitor “Baxdrostat” for resistant hypertension: A clinical approach or futuristic idea?
Open Access
- 5 November 2023
- journal article
- Published by Wiley in Chronic Diseases and Translational Medicine
- Vol. 10 (2) , 146-148
Abstract
No abstract availableThis publication has 8 references indexed in Scilit:
- Clinical Utility of Osilodrostat in Cushing’s Disease: Review of Currently Available LiteratureDrug Design, Development and Therapy, 2023
- Phase 2 Trial of Baxdrostat for Treatment-Resistant HypertensionNew England Journal of Medicine, 2023
- Resistant Hypertension: Detection, Evaluation, and Management: A Scientific Statement From the American Heart AssociationHypertension, 2018
- 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice GuidelinesHypertension, 2018
- Preclinical and Early Clinical Profile of a Highly Selective and Potent Oral Inhibitor of Aldosterone Synthase (CYP11B2)Hypertension, 2017
- Safety profile of mineralocorticoid receptor antagonists: Spironolactone and eplerenoneInternational Journal of Cardiology, 2015
- Aldosterone Excretion Among Subjects With Resistant Hypertension and Symptoms of Sleep ApneaChest, 2004
- Hyperaldosteronism Among Black and White Subjects With Resistant HypertensionHypertension, 2002